Evidence map›Paper›PMID 38958882›Full record

ArticleMolecular imaging and biology2024

Nuclear-Based Labeling of Cellular Immunotherapies: A Simple Protocol for Preclinical Use.

Alessia Volpe, Serge K Lyashchenko, Vladimir Ponomarev

Abstract read
In one paragraph

Article in Molecular imaging and biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alessia VolpeDepartment of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.ORCID 0000-0003-3087-9178
Serge K LyashchenkoDepartment of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Vladimir PonomarevDepartment of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. ponomarv@mskcc.org.ORCID 0000-0002-9119-9128

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Theranostic DLL3/PSMA-bi-specific CAR-T cells for prostate cancer therapyR01CA287491 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Vladimir Ponomarev, Heiko Schoder · 2024 to 2026
$3.6M
Imaging Immune Modulation in Chimeric Antigen Receptor (CAR) T Cell TherapyR01CA204924 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI PONOMAREV, VLADIMIR · 2016 to 2020
$3.5M
Image-guided TRAIL-enhanced CAR T-cell immunotherapyR01CA220524 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI PONOMAREV, VLADIMIR · 2018 to 2022
$2.9M
Multicolor PET to interrogate cancer biologyR01EB033000 · NIBIB · SLOAN-KETTERING INST CAN RESEARCH · PI Jan Grimm, Vladimir Ponomarev · 2023 to 2026
$2.6M
Secretable theranostic payloads to augment the efficacy of adoptive CAR-T cell therapiesR21CA250478 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI PONOMAREV, VLADIMIR · 2020 to 2020
$455k
Fiona and Stanley Druckenmiller Center for Lung Cancer Research Fellowship Award FP00005072NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA204924NCI NIH HHS R01 CA220524NCI NIH HHS R01 CA287491NCI NIH HHS R21 CA250478NIBIB NIH HHS R01 EB033000NIH HHS R01 CA204924NIH HHS R01 CA220524-01A1NIH HHS R21 CA250478The Center for Experimental Immuno-Oncology Fellowship Award FP00001443Tow Foundation Fellowship Award FP000004141
6 · The paper itself

Abstract

Labeling and tracking existing and emerging cell-based immunotherapies using nuclear imaging is widely used to guide the preclinical phases of development and testing of existing and new emerging off-the-shelf cell-based immunotherapies. In fact, advancing our knowledge about their mechanism of action and limitations could provide preclinical support and justification for moving towards clinical experimentation of newly generated products and expedite their approval by the Food and Drug Administration (FDA).Here we provide the reader with a ready to use protocol describing the labeling methodologies and practical procedures to render different candidate cell therapies in vivo traceable by nuclear-based imaging. The protocol includes sufficient practical details to aid researchers at all career stages and from different fields in familiarizing with the described concepts and incorporating them into their work.

Indexed as

ImmunotherapyAnimalsCell NucleusHumansStaining and LabelingCell therapyDirect labelingNuclear imagingPreclinical imagingReporter gene labeling

Identifiers

PMID38958882
PMCPMC11281953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.